Recent investigations have focused on the convergence of GLP-1|GIP|glucagon receptor activator therapies and dopaminergic signaling. While GCGR stimulators are widely employed for managing type 2 diabetes, their potential effects on reinforcement circuits, specifically mediated by DA pathways, are attracting considerable attention. This paper prese